The use of anti-obesity medications (AOMs), such as GLP-1 receptor agonists, continues to accelerate globally, with spending projected to reach nearly $200bn by 2029 (according to the IQVIA Institute for Human Data Science).
ADM’s latest proprietary consumer survey investigates the evolving AOM landscape, detailing two distinct consumer journeys and uncovering how both current users and those transitioning off these medications are reshaping expectations for food, beverage and dietary supplement solutions.
ADM GLP-1 landscape report
ADM's latest proprietary consumer survey examines the evolving AOM landscape, uncovering how both current users and those transitioning off these medications are reshaping expectations for food, beverage and dietary supplement solutions.
The findings detail two distinct consumer journeys.
Current GLP-1 medication users overwhelmingly report satisfaction with their progress.
They also have a strong willingness to invest in solutions that can support them while using AOMs, with a specific focus on portion control and nutritional value.
Those taking GLP-1s have also increased consumption of pre- and probiotics, opening up opportunities for nutraceutical companies to support gastrointestinal health during the weight-loss journey with biotics.
ADM insights also revealed the drivers for consumers stopping GLP-1 medication use, including reaching health goals, side effects or cost.
However, many struggle with weight regain and the return of "food noise," prompting interest in solutions targeting these areas.
Across both groups, the demand for enjoyable and convenient functional products tailored for specific needs is clear.
